Renaissance and GlaxoSmithKline Transfer Nine Products

June 5, 2013

Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's branded division Prestium Pharma, include: 1. Evoclin® (clindamycin phosphate) Foam, 1% 2. Extina® (ketoconazole) Foam, 2% 3. Luxiq® (betamethasone valerate) Foam, 0.12% 4. Olux® (clobetasol propionate) Foam, 0.05% 5. Olux-E® (clobetasol propionate) Foam, 0.05% 6. Vusion® (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum 81.35%) Ointment 7. Zovirax® (acyclovir) Capsules 8. Zovirax® (acyclovir) Tablets 9. Zovirax® (acyclovir) Suspension

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free